Association of bodyweight loss with changes in lipids, blood pressure, and fasting serum glucose following tirzepatide treatment in Japanese participants with type 2 diabetes: A post hoc analysis of the SURPASS J-mono trial.

Mimura H, Oura T, Chin R, Takeuchi M, Fujihara K, Sone H

Journal of diabetes investigation1 Feb 2025Cited by 4 (Europe PMC)

PMID39891527PMCIDPMC12057373DOI10.1111/jdi.14395PepBankPUB-39891527

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study13

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialOther
In Japanese adults with type 2 diabetes on tirzepatide, greater bodyweight loss was associated with greater improvement in metabolic parameters.
In plain wordsIn Japanese adults with type 2 diabetes on tirzepatide, people who lost more weight also saw larger improvements in blood tests and blood pressure.
Peptide
Tirzepatide
Outcome
Not applicableMetabolic parameter improvement by weight loss subgroup
Study
n = 548
Comparator
Dulaglutide 0.75 mg
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
Weight loss subgroups showed greater improvement in metabolic parameters with greater bodyweight loss.
2 context sentences(design, population, supporting numbers)
Summary · context
Metabolic parameter data from tirzepatide-treated participants were analyzed by weight loss subgroups and compared to dulaglutide 0.75 mg.
Summary · context
This analysis included 548 participants (tirzepatide: n = 411, dulaglutide: n = 137).
Report a problemFND-3989152701
02HumanRandomized controlled trialOther
In Japanese adults with type 2 diabetes, bodyweight change had a significant but weak correlation with triglyceride change across treatment groups.
In plain wordsIn Japanese adults with type 2 diabetes, weight change was weakly linked to triglyceride change.
Peptide
Tirzepatide
Outcome
Not applicableCorrelation of bodyweight change with triglycerides change
Study
n = 548
Comparator
Dulaglutide 0.75 mg
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Measurements
Pearson r
0.18 to 0.25 r
triglycerides
Source sentences
Summary
Significant (P < 0.05) but weak correlations between changes in bodyweight and triglycerides (r = 0.18-0.25)
2 context sentences(design, population, supporting numbers)
Summary · context
Metabolic parameter data from tirzepatide-treated participants were analyzed by weight loss subgroups and compared to dulaglutide 0.75 mg.
Summary · context
This analysis included 548 participants (tirzepatide: n = 411, dulaglutide: n = 137).
Report a problemFND-3989152702
03HumanRandomized controlled trialOther
In Japanese adults with type 2 diabetes, bodyweight change had a significant but weak correlation with HDL cholesterol change across treatment groups.
In plain wordsIn Japanese adults with type 2 diabetes, weight change was weakly linked to HDL cholesterol change.
Peptide
Tirzepatide
Outcome
Not applicableCorrelation of bodyweight change with HDL cholesterol change
Study
n = 548
Comparator
Dulaglutide 0.75 mg
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
high-density lipoprotein cholesterol (r = -0.37 to -0.29)
2 context sentences(design, population, supporting numbers)
Summary · context
Metabolic parameter data from tirzepatide-treated participants were analyzed by weight loss subgroups and compared to dulaglutide 0.75 mg.
Summary · context
This analysis included 548 participants (tirzepatide: n = 411, dulaglutide: n = 137).
Report a problemFND-3989152703
04HumanRandomized controlled trialOther
In Japanese adults with type 2 diabetes, bodyweight change had a significant but weak correlation with systolic blood pressure change across treatment groups.
In plain wordsIn Japanese adults with type 2 diabetes, weight change was weakly linked to systolic blood pressure change.
Peptide
Tirzepatide
Outcome
Not applicableCorrelation of bodyweight change with systolic blood pressure change
Study
n = 548
Comparator
Dulaglutide 0.75 mg
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Measurements
Pearson r
0.19 to 0.41 r
systolic blood pressure
Source sentences
Summary
and systolic blood pressure (r = 0.19-0.41)
2 context sentences(design, population, supporting numbers)
Summary · context
Metabolic parameter data from tirzepatide-treated participants were analyzed by weight loss subgroups and compared to dulaglutide 0.75 mg.
Summary · context
This analysis included 548 participants (tirzepatide: n = 411, dulaglutide: n = 137).
Report a problemFND-3989152704
05HumanRandomized controlled trialOther
In Japanese adults with type 2 diabetes, bodyweight change correlated weakly with diastolic blood pressure change in the tirzepatide 5-mg, pooled tirzepatide and dulaglutide 0.75-mg groups.
In plain wordsIn Japanese adults with type 2 diabetes, weight change was weakly linked to diastolic blood pressure change in some treatment groups.
Peptide
Tirzepatide
Outcome
Not applicableCorrelation of bodyweight change with diastolic blood pressure change
Study
n = 548
Comparator
Dulaglutide 0.75 mg
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
in diastolic blood pressure in the tirzepatide 5-mg (r = 0.28), pooled tirzepatide (r = 0.20), and dulaglutide 0.75-mg (r = 0.23) groups; and in fasting serum glucose in the dulaglutide 0.75-mg (r = 0.18) and pooled tirzepatide (r = 0.13) groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Metabolic parameter data from tirzepatide-treated participants were analyzed by weight loss subgroups and compared to dulaglutide 0.75 mg.
Summary · context
This analysis included 548 participants (tirzepatide: n = 411, dulaglutide: n = 137).
Report a problemFND-3989152705
06HumanRandomized controlled trialOther
In Japanese adults with type 2 diabetes, bodyweight change correlated weakly with fasting serum glucose change in the dulaglutide 0.75-mg and pooled tirzepatide groups.
In plain wordsIn Japanese adults with type 2 diabetes, weight change was weakly linked to fasting blood sugar change in two treatment groups.
Peptide
Tirzepatide
Outcome
Not applicableCorrelation of bodyweight change with fasting serum glucose change
Study
n = 548
Comparator
Dulaglutide 0.75 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
and in fasting serum glucose in the dulaglutide 0.75-mg (r = 0.18) and pooled tirzepatide (r = 0.13) groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Metabolic parameter data from tirzepatide-treated participants were analyzed by weight loss subgroups and compared to dulaglutide 0.75 mg.
Summary · context
This analysis included 548 participants (tirzepatide: n = 411, dulaglutide: n = 137).
Report a problemFND-3989152706
07HumanRandomized controlled trialMechanism
In Japanese adults with type 2 diabetes, weight loss was associated with treatment differences between tirzepatide and dulaglutide 0.75 mg to varying degrees across metabolic parameters.
In plain wordsIn Japanese adults with type 2 diabetes, weight loss explained part of the difference between tirzepatide and dulaglutide, more for some measures than others.
Peptide
Tirzepatide
Outcome
Not applicableWeight loss-associated share of treatment differences between tirzepatide and dulaglutide
Study
n = 548
Comparator
Dulaglutide 0.75 mg
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
Weight loss was associated with treatment differences between tirzepatide and dulaglutide 0.75 mg to varying degrees across metabolic parameters
2 context sentences(design, population, supporting numbers)
Summary · context
Metabolic parameter data from tirzepatide-treated participants were analyzed by weight loss subgroups and compared to dulaglutide 0.75 mg.
Summary · context
This analysis included 548 participants (tirzepatide: n = 411, dulaglutide: n = 137).
Report a problemFND-3989152707
08HumanRandomized controlled trialMechanism
In Japanese adults with type 2 diabetes, improvements in fasting serum glucose with tirzepatide versus dulaglutide 0.75 mg had the lowest association with weight loss (36.6%-43.5%).
In plain wordsIn Japanese adults with type 2 diabetes, tirzepatide's fasting blood sugar benefit over dulaglutide depended least on weight loss.
Peptide
Tirzepatide
Outcome
Not applicableWeight loss-associated share of fasting serum glucose treatment difference
Study
n = 548
Comparator
Dulaglutide 0.75 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Measurements
Weight loss association
36.6 to 43.5%
fasting serum glucose
Source sentences
Summary
with improvements in fasting serum glucose having the lowest association with weight loss (36.6%-43.5%).
2 context sentences(design, population, supporting numbers)
Summary · context
Metabolic parameter data from tirzepatide-treated participants were analyzed by weight loss subgroups and compared to dulaglutide 0.75 mg.
Summary · context
This analysis included 548 participants (tirzepatide: n = 411, dulaglutide: n = 137).
Report a problemFND-3989152708

Studies that did not test the peptide alone5

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

09HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In Japanese participants with diabetes receiving dulaglutide, weight and diastolic blood pressure changes correlated positively.
In plain wordsIn Japanese participants with diabetes receiving dulaglutide, weight and diastolic blood pressure changes were positively linked.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseWeight change correlation with diastolic blood pressure change
Study
n = 137
Outcome group
Blood pressure · Cardiovascular
Measurements
Pearson correlation
0.23 r
dulaglutide group
Source sentences
Summary
in diastolic blood pressure in the tirzepatide 5-mg (r = 0.28), pooled tirzepatide (r = 0.20), and dulaglutide 0.75-mg (r = 0.23) groups;
2 context sentences(design, population, supporting numbers)
Summary · context
Metabolic parameter data from tirzepatide-treated participants were analyzed by weight loss subgroups and compared to dulaglutide 0.75 mg. Correlations between changes from baseline to week 52 in weight loss and each metabolic parameter were assessed; Pearson correlation coefficients were derived.
Summary · context
This analysis included 548 participants (tirzepatide: n = 411, dulaglutide: n = 137).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3989152712
10HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In Japanese participants with diabetes receiving dulaglutide, weight and fasting serum glucose changes correlated positively.
In plain wordsIn Japanese participants with diabetes receiving dulaglutide, weight and fasting blood sugar changes were positively linked.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseWeight change correlation with fasting serum glucose change
Study
n = 137
Outcome group
Glycemic control · Metabolic and weight
Measurements
Pearson correlation
0.18 r
dulaglutide group
Source sentences
Summary
and in fasting serum glucose in the dulaglutide 0.75-mg (r = 0.18) and pooled tirzepatide (r = 0.13) groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Metabolic parameter data from tirzepatide-treated participants were analyzed by weight loss subgroups and compared to dulaglutide 0.75 mg. Correlations between changes from baseline to week 52 in weight loss and each metabolic parameter were assessed; Pearson correlation coefficients were derived.
Summary · context
This analysis included 548 participants (tirzepatide: n = 411, dulaglutide: n = 137).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3989152713
11HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In Japanese participants with diabetes, weight and triglyceride changes correlated weakly across treatment groups including dulaglutide.
In plain wordsIn Japanese participants with diabetes, weight and blood fat changes were weakly linked across treatment groups including dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseWeight change correlation with triglyceride change
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Measurements
Pearson correlation
0.18 to 0.25 r
across treatment groups
Source sentences
Summary
Significant (P < 0.05) but weak correlations between changes in bodyweight and triglycerides (r = 0.18-0.25), high-density lipoprotein cholesterol (r = -0.37 to -0.29), and systolic blood pressure (r = 0.19-0.41) were observed across treatment groups
2 context sentences(design, population, supporting numbers)
Summary · context
Metabolic parameter data from tirzepatide-treated participants were analyzed by weight loss subgroups and compared to dulaglutide 0.75 mg. Correlations between changes from baseline to week 52 in weight loss and each metabolic parameter were assessed; Pearson correlation coefficients were derived.
Summary · context
This analysis included 548 participants (tirzepatide: n = 411, dulaglutide: n = 137).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3989152709
12HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In Japanese participants with diabetes, weight and HDL cholesterol changes correlated negatively across treatment groups including dulaglutide.
In plain wordsIn Japanese participants with diabetes, weight and HDL cholesterol changes showed a negative link across treatment groups including dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseWeight change correlation with HDL cholesterol change
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Measurements
Pearson correlation
−0.37 to −0.29 r
across treatment groups
Source sentences
Summary
Significant (P < 0.05) but weak correlations between changes in bodyweight and triglycerides (r = 0.18-0.25), high-density lipoprotein cholesterol (r = -0.37 to -0.29), and systolic blood pressure (r = 0.19-0.41) were observed across treatment groups
2 context sentences(design, population, supporting numbers)
Summary · context
Metabolic parameter data from tirzepatide-treated participants were analyzed by weight loss subgroups and compared to dulaglutide 0.75 mg. Correlations between changes from baseline to week 52 in weight loss and each metabolic parameter were assessed; Pearson correlation coefficients were derived.
Summary · context
This analysis included 548 participants (tirzepatide: n = 411, dulaglutide: n = 137).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3989152710
13HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In Japanese participants with diabetes, weight and systolic blood pressure changes correlated weakly across treatment groups including dulaglutide.
In plain wordsIn Japanese participants with diabetes, weight and systolic blood pressure changes were weakly linked across treatment groups including dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseWeight change correlation with systolic blood pressure change
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Measurements
Pearson correlation
0.19 to 0.41 r
across treatment groups
Source sentences
Summary
Significant (P < 0.05) but weak correlations between changes in bodyweight and triglycerides (r = 0.18-0.25), high-density lipoprotein cholesterol (r = -0.37 to -0.29), and systolic blood pressure (r = 0.19-0.41) were observed across treatment groups
2 context sentences(design, population, supporting numbers)
Summary · context
Metabolic parameter data from tirzepatide-treated participants were analyzed by weight loss subgroups and compared to dulaglutide 0.75 mg. Correlations between changes from baseline to week 52 in weight loss and each metabolic parameter were assessed; Pearson correlation coefficients were derived.
Summary · context
This analysis included 548 participants (tirzepatide: n = 411, dulaglutide: n = 137).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3989152711

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 8Current
28 Oct 2026, 02:03 UTC
The same notice was added 5 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.